Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $1.15 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.13, down -1.74%. In other words, the price has decreased by -$1.74 from its previous closing price. On the day, 0.97 million shares were traded. FATE stock price reached its highest trading level at $1.1897 during the session, while it also had its lowest trading level at $1.13.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 129535288 and an Enterprise Value of -28704016. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.71 while its Price-to-Book (P/B) ratio in mrq is 0.45. Its current Enterprise Value per Revenue stands at -2.153 whereas that against EBITDA is 0.171.
Stock Price History:
The Beta on a monthly basis for FATE is 2.25, which has changed by -0.752193 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -5.64%, while the 200-Day Moving Average is calculated to be -30.46%.
Shares Statistics:
The stock has traded on average 1.90M shares per day over the past 3-months and 1147550 shares per day over the last 10 days, according to various share statistics. A total of 114.60M shares are outstanding, with a floating share count of 107.09M. Insiders hold about 6.58% of the company’s shares, while institutions hold 83.99% stake in the company. Shares short for FATE as of 1749772800 were 9512319 with a Short Ratio of 5.03, compared to 1747267200 on 12870954. Therefore, it implies a Short% of Shares Outstanding of 9512319 and a Short% of Float of 9.4799995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
